English
Insider transactions
EDGARCOGENT BIOSCIENCES, INC.
Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, read from each filing’s XML. Codes and their wording are the SEC’s own.
A Form 4 is due within two business days of the transaction, so the most recent trades may not be filed yet.
Window: transactions dated on or after 2025-11-21.
- Open-market purchases (code P)
- 0 transactions, — shares
- Open-market sales (code S)
- 8 transactions, 10,860,152 shares
- Sum of shares × price per share: 383,888,198.3581
Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.
Showing 1–50 of 50
| Date | Reporting owner | Code | Acquired or disposed | Shares | Price per share, as filed | Value (derived) | Shares owned after | Direct or indirect | Rule 10b5-1 box | Notes | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-01 Filed 2026-10-05 | Ferrante Karen Jean Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 759 | 0 | — | 759 | Direct (D) | No | F1
| Open filing 0001193125-26-414218 Read from the filing’s XML Dispute this row |
| 2026-08-27 Filed 2026-08-31 | Morris Arlene Director | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Acquired (A) | 41,927 | 5.64 | 236,468.28Derived: shares × price per share. Exact value 236468.28. | 41,927 | Direct (D) | Yes | F1
| Open filing 0001193125-26-377001 Read from the filing’s XML Dispute this row |
| 2026-08-27 Filed 2026-08-31 | Morris Arlene Director | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Acquired (A) | 3,583 | 2.52 | 9,029.16Derived: shares × price per share. Exact value 9029.16. | 45,510 | Direct (D) | Yes | F1
| Open filing 0001193125-26-377001 Read from the filing’s XML Dispute this row |
| 2026-08-27 Filed 2026-08-31 | Morris Arlene Director | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 42,349 | 37.0925 | 1,570,830.2825Derived: shares × price per share. Exact value 1570830.2825. | 3,161 | Direct (D) | Yes | F1, F2
| Open filing 0001193125-26-377001 Read from the filing’s XML Dispute this row |
| 2026-08-27 Filed 2026-08-31 | Morris Arlene Director | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 3,161 | 37.5396 | 118,662.6756Derived: shares × price per share. Exact value 118662.6756. | 0 | Direct (D) | Yes | F1, F3
| Open filing 0001193125-26-377001 Read from the filing’s XML Dispute this row |
| 2026-08-27 Filed 2026-08-31 | Morris Arlene Director | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Disposed (D) | 41,927 | 0 | — | 2,773 | Direct (D) | Yes | F1, F4
| Open filing 0001193125-26-377001 Read from the filing’s XML Dispute this row |
| 2026-08-27 Filed 2026-08-31 | Morris Arlene Director | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Disposed (D) | 3,583 | 0 | — | 0 | Direct (D) | Yes | F1, F4
| Open filing 0001193125-26-377001 Read from the filing’s XML Dispute this row |
| 2026-07-01 Filed 2026-07-06 | Ferrante Karen Jean Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 627 | 0 | — | 627 | Direct (D) | No | F1
| Open filing 0001193125-26-296249 Read from the filing’s XML Dispute this row |
| 2026-06-09 Filed 2026-06-11 | Harwin Peter Evan Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 17,901 | 0 | — | 17,901 | Direct (D) | No | F1, F2
| Open filing 0001193125-26-267665 Read from the filing’s XML Dispute this row |
| 2026-06-09 Filed 2026-06-11 | Ros Matthew Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 17,901 | 0 | — | 17,901 | Direct (D) | No | F1
| Open filing 0001193125-26-267666 Read from the filing’s XML Dispute this row |
| 2026-06-09 Filed 2026-06-11 | Ferrante Karen Jean Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 17,901 | 0 | — | 17,901 | Direct (D) | No | F1
| Open filing 0001193125-26-267663 Read from the filing’s XML Dispute this row |
| 2026-06-09 Filed 2026-06-11 | CAIN CHRISTOPHER W. Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 17,901 | 0 | — | 17,901 | Direct (D) | No | F1, F2
| Open filing 0001193125-26-267662 Read from the filing’s XML Dispute this row |
| 2026-06-09 Filed 2026-06-11 | Shegog Todd Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 17,901 | 0 | — | 17,901 | Direct (D) | No | F1
| Open filing 0001193125-26-267670 Read from the filing’s XML Dispute this row |
| 2026-06-09 Filed 2026-06-11 | Morris Arlene Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 17,901 | 0 | — | 17,901 | Direct (D) | No | F1
| Open filing 0001193125-26-267667 Read from the filing’s XML Dispute this row |
| 2026-05-19 Filed 2026-05-21 | Robbins Andrew R Director · Officer: President and CEO | GBona fide gift | Disposed (D) | 160,000 | 0 | — | 497,503 | Direct (D) | No | F1
| Open filing 0001193125-26-234578 Read from the filing’s XML Dispute this row |
| 2026-05-19 Filed 2026-05-21 | Robbins Andrew R Director · Officer: President and CEO | GBona fide gift | Acquired (A) | 160,000 | 0 | — | 160,000 | Indirect (I) By trust | No | F1
| Open filing 0001193125-26-234578 Read from the filing’s XML Dispute this row |
| 2026-04-01 Filed 2026-04-03 | Ferrante Karen Jean Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 686 | 0.00 | 0Derived: shares × price per share. Exact value 0.00. | 686 | Direct (D) | No | F1
| Open filing 0001193125-26-142082 Read from the filing’s XML Dispute this row |
| 2026-03-31 Filed 2026-03-31 | Fairmount Funds Management LLC Director | CConversion of derivative security | Acquired (A) | 7,000,000 | — | — | 12,503,418 | Indirect (I) Fairmount Healthcare Fund II LP | No | F1, F2
| Open filing 0001104659-26-038057 Read from the filing’s XML Dispute this row |
| 2026-03-31 Filed 2026-03-31 | Fairmount Funds Management LLC Director | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 7,000,000 | 34.66 | 242,620,000Derived: shares × price per share. Exact value 242620000.00. | 5,503,418 | Indirect (I) Fairmount Healthcare Fund II LP | No | F2
| Open filing 0001104659-26-038057 Read from the filing’s XML Dispute this row |
| 2026-03-31 Filed 2026-03-31 | Fairmount Funds Management LLC Director | CConversion of derivative security | Disposed (D) | 28,000 | 0.00 | 0Derived: shares × price per share. Exact value 0.00. | 39,414 | Indirect (I) Fairmount Healthcare Fund II LP | No | F1, F2
| Open filing 0001104659-26-038057 Read from the filing’s XML Dispute this row |
| 2026-01-22 Filed 2026-01-22 | Fairmount Funds Management LLC Director | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 3,500,000 | 36.40 | 127,400,000Derived: shares × price per share. Exact value 127400000.00. | 5,503,418 | Indirect (I) Fairmount Healthcare Fund II LP | No | F1
| Open filing 0001104659-26-005924 Read from the filing’s XML Dispute this row |
| 2026-01-01 Filed 2026-01-05 | Ferrante Karen Jean Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 643 | 0.00 | 0Derived: shares × price per share. Exact value 0.00. | 643 | Direct (D) | No | F1
| Open filing 0001193125-26-002367 Read from the filing’s XML Dispute this row |
| 2025-12-26 Filed 2025-12-30 | Robinson John Edward Officer: Chief Scientific Officer | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 90,000 | 38.74 | 3,486,600Derived: shares × price per share. Exact value 3486600.00. | 140,002 | Direct (D) | No | F1, F2
| Open filing 0001193125-25-337049 Read from the filing’s XML Dispute this row |
| 2025-12-26 Filed 2025-12-30 | Green John L. Officer: Chief Financial Officer | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 77,000 | 38.68 | 2,978,360Derived: shares × price per share. Exact value 2978360.00. | 131,834 | Direct (D) | No | F1, F2
| Open filing 0001193125-25-337051 Read from the filing’s XML Dispute this row |
| 2025-12-26 Filed 2025-12-30 | Kearns Evan Officer: Chief Legal Officer | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 65,000 | 38.70 | 2,515,500Derived: shares × price per share. Exact value 2515500.00. | 109,398 | Direct (D) | No | F1, F2
| Open filing 0001193125-25-337052 Read from the filing’s XML Dispute this row |
| 2025-12-26 Filed 2025-12-30 | Sachs Jessica Officer: Chief Medical Officer | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 82,642 | 38.70 | 3,198,245.4Derived: shares × price per share. Exact value 3198245.40. | 133,938 | Direct (D) | No | F1, F2
| Open filing 0001193125-25-337050 Read from the filing’s XML Dispute this row |
| 2025-12-17 Filed 2025-12-19 | Robbins Andrew R Director · Officer: President and CEO | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 185,000 | 0 | — | 185,000 | Direct (D) | No | F1
| Open filing 0001193125-25-326775 Read from the filing’s XML Dispute this row |
| 2025-12-17 Filed 2025-12-19 | Robbins Andrew R Director · Officer: President and CEO | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 840,000 | 0 | — | 1,025,000 | Direct (D) | No | F2
| Open filing 0001193125-25-326775 Read from the filing’s XML Dispute this row |
| 2025-12-17 Filed 2025-12-19 | Robbins Andrew R Director · Officer: President and CEO | FPayment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | Disposed (D) | 367,497 | 39.45 | 14,497,756.65Derived: shares × price per share. Exact value 14497756.65. | 657,503 | Direct (D) | No | F3, F4
| Open filing 0001193125-25-326775 Read from the filing’s XML Dispute this row |
| 2025-12-17 Filed 2025-12-19 | Robbins Andrew R Director · Officer: President and CEO | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 245,000 | 0.00 | 0Derived: shares × price per share. Exact value 0.00. | 245,000 | Direct (D) | No | F5
| Open filing 0001193125-25-326775 Read from the filing’s XML Dispute this row |
| 2025-12-17 Filed 2025-12-19 | Pinnow Cole Officer: Chief Commercial Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 50,000 | 0 | — | 97,450 | Direct (D) | No | F1, F2
| Open filing 0001193125-25-326774 Read from the filing’s XML Dispute this row |
| 2025-12-17 Filed 2025-12-19 | Pinnow Cole Officer: Chief Commercial Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 214,000 | 0 | — | 311,450 | Direct (D) | No | F3
| Open filing 0001193125-25-326774 Read from the filing’s XML Dispute this row |
| 2025-12-17 Filed 2025-12-19 | Pinnow Cole Officer: Chief Commercial Officer | FPayment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | Disposed (D) | 94,800 | 39.45 | 3,739,860Derived: shares × price per share. Exact value 3739860.00. | 216,650 | Direct (D) | No | F4, F5
| Open filing 0001193125-25-326774 Read from the filing’s XML Dispute this row |
| 2025-12-17 Filed 2025-12-19 | Pinnow Cole Officer: Chief Commercial Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 65,000 | 0.00 | 0Derived: shares × price per share. Exact value 0.00. | 65,000 | Direct (D) | No | F6
| Open filing 0001193125-25-326774 Read from the filing’s XML Dispute this row |
| 2025-12-17 Filed 2025-12-19 | Green John L. Officer: Chief Financial Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 50,000 | 0 | — | 53,841 | Direct (D) | No | F1
| Open filing 0001193125-25-326771 Read from the filing’s XML Dispute this row |
| 2025-12-17 Filed 2025-12-19 | Green John L. Officer: Chief Financial Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 300,000 | 0 | — | 353,841 | Direct (D) | No | F2
| Open filing 0001193125-25-326771 Read from the filing’s XML Dispute this row |
| 2025-12-17 Filed 2025-12-19 | Green John L. Officer: Chief Financial Officer | FPayment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | Disposed (D) | 145,007 | 39.45 | 5,720,526.15Derived: shares × price per share. Exact value 5720526.15. | 208,834 | Direct (D) | No | F3, F4
| Open filing 0001193125-25-326771 Read from the filing’s XML Dispute this row |
| 2025-12-17 Filed 2025-12-19 | Green John L. Officer: Chief Financial Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 65,000 | 0.00 | 0Derived: shares × price per share. Exact value 0.00. | 65,000 | Direct (D) | No | F5
| Open filing 0001193125-25-326771 Read from the filing’s XML Dispute this row |
| 2025-12-17 Filed 2025-12-19 | Sachs Jessica Officer: Chief Medical Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 50,000 | 0 | — | 51,296 | Direct (D) | No | F1
| Open filing 0001193125-25-326773 Read from the filing’s XML Dispute this row |
| 2025-12-17 Filed 2025-12-19 | Sachs Jessica Officer: Chief Medical Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 320,000 | 0 | — | 371,296 | Direct (D) | No | F2
| Open filing 0001193125-25-326773 Read from the filing’s XML Dispute this row |
| 2025-12-17 Filed 2025-12-19 | Sachs Jessica Officer: Chief Medical Officer | FPayment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | Disposed (D) | 154,716 | 39.45 | 6,103,546.2Derived: shares × price per share. Exact value 6103546.20. | 216,580 | Direct (D) | No | F3, F4
| Open filing 0001193125-25-326773 Read from the filing’s XML Dispute this row |
| 2025-12-17 Filed 2025-12-19 | Sachs Jessica Officer: Chief Medical Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 65,000 | 0.00 | 0Derived: shares × price per share. Exact value 0.00. | 65,000 | Direct (D) | No | F5
| Open filing 0001193125-25-326773 Read from the filing’s XML Dispute this row |
| 2025-12-17 Filed 2025-12-19 | Robinson John Edward Officer: Chief Scientific Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 50,000 | 0 | — | 50,000 | Direct (D) | No | F1
| Open filing 0001193125-25-326776 Read from the filing’s XML Dispute this row |
| 2025-12-17 Filed 2025-12-19 | Robinson John Edward Officer: Chief Scientific Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 320,000 | 0 | — | 370,000 | Direct (D) | No | F2
| Open filing 0001193125-25-326776 Read from the filing’s XML Dispute this row |
| 2025-12-17 Filed 2025-12-19 | Robinson John Edward Officer: Chief Scientific Officer | FPayment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | Disposed (D) | 139,998 | 39.45 | 5,522,921.1Derived: shares × price per share. Exact value 5522921.10. | 230,002 | Direct (D) | No | F3, F4
| Open filing 0001193125-25-326776 Read from the filing’s XML Dispute this row |
| 2025-12-17 Filed 2025-12-19 | Robinson John Edward Officer: Chief Scientific Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 65,000 | 0.00 | 0Derived: shares × price per share. Exact value 0.00. | 65,000 | Direct (D) | No | F5
| Open filing 0001193125-25-326776 Read from the filing’s XML Dispute this row |
| 2025-12-17 Filed 2025-12-19 | Kearns Evan Officer: Chief Legal Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 40,000 | 0 | — | 40,000 | Direct (D) | No | F1
| Open filing 0001193125-25-326772 Read from the filing’s XML Dispute this row |
| 2025-12-17 Filed 2025-12-19 | Kearns Evan Officer: Chief Legal Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 260,000 | 0 | — | 300,000 | Direct (D) | No | F2
| Open filing 0001193125-25-326772 Read from the filing’s XML Dispute this row |
| 2025-12-17 Filed 2025-12-19 | Kearns Evan Officer: Chief Legal Officer | FPayment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | Disposed (D) | 125,602 | 39.45 | 4,954,998.9Derived: shares × price per share. Exact value 4954998.90. | 174,398 | Direct (D) | No | F3, F4
| Open filing 0001193125-25-326772 Read from the filing’s XML Dispute this row |
| 2025-12-17 Filed 2025-12-19 | Kearns Evan Officer: Chief Legal Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 55,000 | 0.00 | 0Derived: shares × price per share. Exact value 0.00. | 55,000 | Direct (D) | No | F5
| Open filing 0001193125-25-326772 Read from the filing’s XML Dispute this row |
Institutional holders (Form 13F)
Quarter ending 2026-09-30: 8,935 filings read, the latest filed 2026-11-20. Prior quarter ending 2026-06-30: 9,178 filings read.
Showing 1–27 of 27
| Manager | Shares or principal | Value as filed | Change from the prior quarter | Source |
|---|---|---|---|---|
| Linden Advisors LP | 83,909,000 PRN | 91,220,134 dollars | Lower by 5,256,000 Prior quarter: 89,165,000 | Open filing 0001193125-26-462390 Filed 2026-11-16 Dispute this row |
| WOLVERINE ASSET MANAGEMENT LLC Partly reported under another manager | 40,031,000 PRN | 43,122,830 dollars | Higher by 10,531,000 Prior quarter: 29,500,000 | Open filing 0001279891-26-000016 Filed 2026-11-02 Dispute this row |
| Calamos Advisors LLC | 15,341,000 PRN | 16,562,911 dollars | Lower by 2,073,000 Prior quarter: 17,414,000 | Open filing 0001316507-26-000004 Filed 2026-11-02 Dispute this row |
| READYSTATE ASSET MANAGEMENT LP | 12,500,000 PRN | 13,481,250 dollars | Higher by 10,000,000 Prior quarter: 2,500,000 | Open filing 0001214659-26-014366 Filed 2026-11-16 Dispute this row |
| Affinity Asset Advisors, LLC | 11,000,000 PRN | 12,054,793 dollars | Unchanged Prior quarter: 11,000,000 | Open filing 0001011438-26-000687 Filed 2026-11-13 Dispute this row |
| BROOKFIELD Corp /ON/ Partly reported under another manager | 9,802,000 PRN | 10,741,916 dollars | Not in the prior quarter’s filings read | Open filing 0001193125-26-467250 Filed 2026-11-18 Dispute this row |
| LORD, ABBETT CO. LLC | 8,141,000 PRN | 8,900 dollars | Lower by 11,000 Prior quarter: 8,152,000 | Open filing 0000930413-26-003314 Filed 2026-11-13 Dispute this row |
| Wellesley Asset Management | 7,550,000 PRN | 6,013,841 dollars | Higher by 300,000 Prior quarter: 7,250,000 | Open filing 0001533551-26-000009 Filed 2026-11-12 Dispute this row |
| AMERIPRISE FINANCIAL INC Partly reported under another manager | 6,000,000 PRN | 6,582,175 dollars | Unchanged Prior quarter: 6,000,000 | Open filing 0001193125-26-463125 Filed 2026-11-16 Dispute this row |
| ADVENT CAPITAL MANAGEMENT /DE/ | 4,302,000 PRN | 4,740,930 dollars | Lower by 163,000 Prior quarter: 4,465,000 | Open filing 0001140361-26-042650 Filed 2026-11-09 Dispute this row |
| GABELLI FUNDS LLC | 4,250,000 PRN | 4,588,513 dollars | Not in the prior quarter’s filings read | Open filing 0001140361-26-043450 Filed 2026-11-12 Dispute this row |
| Jefferies Financial Group Inc. Partly reported under another manager | 4,097,000 PRN | 4,415,212 dollars | Higher by 3,943,000 Prior quarter: 154,000 | Open filing 0000096223-26-000034 Filed 2026-11-05 Dispute this row |
| SSI INVESTMENT MANAGEMENT LLC | 3,897,000 PRN | 4,251,201 dollars | Lower by 356,000 Prior quarter: 4,253,000 | Open filing 0001172661-26-004930 Filed 2026-11-10 Dispute this row |
| MILLENNIUM MANAGEMENT LLC | 2,000,000 PRN | 2,153,264 dollars | Unchanged Prior quarter: 2,000,000 | Open filing 0001273087-26-000011 Filed 2026-11-16 Dispute this row |
| FMR LLC Partly reported under another manager | 1,535,000 PRN | 1,674,517 dollars | Unchanged Prior quarter: 1,535,000 | Open filing 0000315066-26-002964 Filed 2026-11-10 Dispute this row |
| BANK OF AMERICA CORP /DE/ Partly reported under another manager | 1,103,000 PRN | 1,203,252 dollars | Higher by 3,000 Prior quarter: 1,100,000 | Open filing 0000070858-26-000589 Filed 2026-11-16 Dispute this row |
| AGF MANAGEMENT LTD Partly reported under another manager | 1,000,000 PRN | 1,090,890 dollars | Unchanged Prior quarter: 1,000,000 | Open filing 0000945621-26-001335 Filed 2026-11-03 Dispute this row |
| Kohlberg Kravis Roberts Co. L.P. Partly reported under another manager | 500,000 PRN | 547,945 dollars | Lower by 490,000 Prior quarter: 990,000 | Open filing 0001399770-26-000010 Filed 2026-11-13 Dispute this row |
| BNP PARIBAS FINANCIAL MARKETS Partly reported under another manager | 438,000 PRN | 477,810 dollars | Unchanged Prior quarter: 438,000 | Open filing 0001166588-26-000012 Filed 2026-11-12 Dispute this row |
| Calamos Wealth Management LLC | 290,000 PRN | 313,099 dollars | Higher by 22,000 Prior quarter: 268,000 | Open filing 0001455258-26-000004 Filed 2026-11-02 Dispute this row |
| LAZARD ASSET MANAGEMENT LLC | 262,000 PRN | 2,871 dollars | Unchanged Prior quarter: 262,000 | Open filing 0001207017-26-000051 Filed 2026-11-16 Dispute this row |
| Central Pacific Bank - Trust Division Partly reported under another manager | 230,000 PRN | 250,905 dollars | Unchanged Prior quarter: 230,000 | Open filing 0002020066-26-000006 Filed 2026-10-06 Dispute this row |
| GROUP ONE TRADING LLC Option: Call | 58,600 SH | 1,876,372 dollars | Lower by 111,000 Prior quarter: 169,600 | Open filing 0000932540-26-000017 Filed 2026-11-10 Dispute this row |
| SIMPLEX TRADING, LLC Option: Call | 42,100 SH | 1,348,042 dollars | Lower by 19,000 Prior quarter: 61,100 | Open filing 0001488542-26-000013 Filed 2026-11-04 Dispute this row |
| HRT FINANCIAL LP | 35,000 SH | 1,120 dollars | Higher by 25,000 Prior quarter: 10,000 | Open filing 0001475597-26-000249 Filed 2026-11-13 Dispute this row |
| SIMPLEX TRADING, LLC Option: Put | 24,000 SH | 768,480 dollars | Lower by 20,600 Prior quarter: 44,600 | Open filing 0001488542-26-000013 Filed 2026-11-04 Dispute this row |
| GROUP ONE TRADING LLC Option: Put | 18,200 SH | 582,764 dollars | Higher by 4,200 Prior quarter: 14,000 | Open filing 0000932540-26-000017 Filed 2026-11-10 Dispute this row |
Managers in the prior quarter with no filing read for the latest
They may simply not have filed yet: absent from the latest quarter’s filings read is not the same as a position sold.
- Jump Financial, LLC 11,944,000 PRN
- OAKTREE CAPITAL MANAGEMENT LP 11,890,000 PRN
- Jupiter Topco LLC 3,922,000 SH
- ORBIMED ADVISORS LLC 1,000,000 PRN
- Form 13F covers long positions in Section 13(f) securities only: no short positions and no securities outside that list.
- Reports for quarters ending before 2013-06-30 were filed as plain text and are not read.
- A manager that has not yet filed for the latest quarter is absent, not at zero; filings are due up to 45 days after quarter end.
- A change is the difference between two quarter-end snapshots, not a trade.
- A position reported under another manager may also appear in that manager’s filing; rows are not added together.
- Holdings the securities list cannot place with this company, or places ambiguously, are not shown.
Trades by members of Congress
Periodic transaction reports filed by U.S. House members that name this company’s stock. Dates and amounts are as filed.
Showing 1–1 of 1
| Member | Transaction date | Type | Amount | Owner | Report |
|---|---|---|---|---|---|
| Hon. Christopher L. Jacobs (NY27) | 2022-12-12 | Purchase | $1,001 - $15,000 | 2023-01-20 |
5% holders (Schedule 13D and 13G)
Schedules filed in the SEC’s structured format (late 2024 onward) are read here. Earlier schedules are free text and are not read.
| Holder | Percent of class | Shares held | Event date | Form | Source |
|---|---|---|---|---|---|
| Deerfield Mgmt, L.P. Common Stock | 2.88 | 5,006,104.00 | 06/30/2026 Filed 2026-08-13 | SCHEDULE 13G/AAmendment 2 | Open filing 0001193805-26-001082 Dispute this row |
| Deerfield Management Company, L.P. Common Stock | 2.88 | 5,006,104.00 | 06/30/2026 Filed 2026-08-13 | SCHEDULE 13G/AAmendment 2 | Open filing 0001193805-26-001082 Dispute this row |
| Deerfield Partners, L.P. Common Stock | 2.88 | 5,006,104.00 | 06/30/2026 Filed 2026-08-13 | SCHEDULE 13G/AAmendment 2 | Open filing 0001193805-26-001082 Dispute this row |
| James E. Flynn Common Stock | 2.88 | 5,006,104.00 | 06/30/2026 Filed 2026-08-13 | SCHEDULE 13G/AAmendment 2 | Open filing 0001193805-26-001082 Dispute this row |
| Vanguard Capital Management Common Stock | 5.08 | 8,691,589 | 06/30/2026 Filed 2026-07-31 | SCHEDULE 13G | Open filing 0002100119-26-001323 Dispute this row |
| BlackRock, Inc. Common Stock | 8.0 | 13,593,063 | 06/30/2026 Filed 2026-07-27 | SCHEDULE 13G/AAmendment 3 | Open filing 0002012383-26-002235 Dispute this row |
| Deerfield Mgmt, L.P. Common Stock | 5.29 | 9,043,903.00 | 03/31/2026 Filed 2026-05-14 | SCHEDULE 13G/AAmendment 1 | Open filing 0001193805-26-000609 Dispute this row |
| Deerfield Management Company, L.P. Common Stock | 5.29 | 9,043,903.00 | 03/31/2026 Filed 2026-05-14 | SCHEDULE 13G/AAmendment 1 | Open filing 0001193805-26-000609 Dispute this row |
| Deerfield Partners, L.P. Common Stock | 5.29 | 9,043,903.00 | 03/31/2026 Filed 2026-05-14 | SCHEDULE 13G/AAmendment 1 | Open filing 0001193805-26-000609 Dispute this row |
| James E. Flynn Common Stock | 5.29 | 9,043,903.00 | 03/31/2026 Filed 2026-05-14 | SCHEDULE 13G/AAmendment 1 | Open filing 0001193805-26-000609 Dispute this row |
| Fairmount Funds Management LLC Common Stock, $0.001 par value | 8.6 | 15,356,918.00 | 03/31/2026 Filed 2026-03-31 | SCHEDULE 13D/AAmendment 10 | Open filing 0001104659-26-038056 Dispute this row |
| Fairmount Healthcare Fund II GP LLC Common Stock, $0.001 par value | 8.6 | 15,356,918.00 | 03/31/2026 Filed 2026-03-31 | SCHEDULE 13D/AAmendment 10 | Open filing 0001104659-26-038056 Dispute this row |
| The Vanguard Group Common Stock | 0 | 0 | 03/13/2026 Filed 2026-03-26 | SCHEDULE 13G/AAmendment 2 | Open filing 0000102909-26-000905 Dispute this row |
| Fairmount Funds Management LLC Common Stock, $0.001 par value | 9.9 | 16,261,918.00 | 01/22/2026 Filed 2026-01-22 | SCHEDULE 13D/AAmendment 9 | Open filing 0001104659-26-005917 Dispute this row |
| Fairmount Healthcare Fund II GP LLC Common Stock, $0.001 par value | 9.9 | 16,261,918.00 | 01/22/2026 Filed 2026-01-22 | SCHEDULE 13D/AAmendment 9 | Open filing 0001104659-26-005917 Dispute this row |
| Kynam Capital Management, LP Common Stock, par value $0.001 | 4.33 | 6,165,223 | 12/31/2025 Filed 2026-02-17 | SCHEDULE 13G/AAmendment 2 | Open filing 0001907884-26-000002 Dispute this row |
| Kynam Capital Management GP, LLC Common Stock, par value $0.001 | 4.33 | 6,165,223 | 12/31/2025 Filed 2026-02-17 | SCHEDULE 13G/AAmendment 2 | Open filing 0001907884-26-000002 Dispute this row |
| Yue Tang Common Stock, par value $0.001 | 4.33 | 6,165,223 | 12/31/2025 Filed 2026-02-17 | SCHEDULE 13G/AAmendment 2 | Open filing 0001907884-26-000002 Dispute this row |
| Commodore Capital LP Common Stock, $0.001 par value per share | 1.8 | 2,802,905.00 | 12/31/2025 Filed 2026-02-17 | SCHEDULE 13G/AAmendment 2 | Open filing 0001831942-26-000011 Dispute this row |
| Commodore Capital Master LP Common Stock, $0.001 par value per share | 1.8 | 2,802,905.00 | 12/31/2025 Filed 2026-02-17 | SCHEDULE 13G/AAmendment 2 | Open filing 0001831942-26-000011 Dispute this row |
| Robert Egen Atkinson Common Stock, $0.001 par value per share | 1.8 | 2,802,905.00 | 12/31/2025 Filed 2026-02-17 | SCHEDULE 13G/AAmendment 2 | Open filing 0001831942-26-000011 Dispute this row |
| Michael Kramarz Common Stock, $0.001 par value per share | 1.8 | 2,802,905.00 | 12/31/2025 Filed 2026-02-17 | SCHEDULE 13G/AAmendment 2 | Open filing 0001831942-26-000011 Dispute this row |
| The Vanguard Group Common Stock | 7.50 | 11,514,326 | 12/31/2025 Filed 2026-01-30 | SCHEDULE 13G/AAmendment 1 | Open filing 0000102909-26-000056 Dispute this row |
| BlackRock, Inc. Common Stock | 6.5 | 11,370,224.00 | 12/31/2025 Filed 2026-01-21 | SCHEDULE 13G/AAmendment 2 | Open filing 0002012383-26-000802 Dispute this row |
| BlackRock, Inc. Common Stock | 6.5 | 11,370,224 | 12/31/2025 Filed 2026-01-21 | SCHEDULE 13G/AAmendment 2 | Open filing 0002012383-26-000657 Dispute this row |
| Fairmount Funds Management LLC Common Stock, $0.001 par value | 9.9 | 15,877,418.00 | 11/13/2025 Filed 2025-11-17 | SCHEDULE 13D/AAmendment 8 | Open filing 0001104659-25-113219 Dispute this row |
| Fairmount Healthcare Fund II GP LLC Common Stock, $0.001 par value | 9.9 | 15,877,418.00 | 11/13/2025 Filed 2025-11-17 | SCHEDULE 13D/AAmendment 8 | Open filing 0001104659-25-113219 Dispute this row |
| Commodore Capital LP Common Stock, $0.001 Par Value | 7.2 | 10,208,060.00 | 09/30/2025 Filed 2025-11-14 | SCHEDULE 13G/AAmendment 1 | Open filing 0001831942-25-000029 Dispute this row |
| Commodore Capital Master LP Common Stock, $0.001 Par Value | 7.2 | 10,208,060.00 | 09/30/2025 Filed 2025-11-14 | SCHEDULE 13G/AAmendment 1 | Open filing 0001831942-25-000029 Dispute this row |
| Robert Egen Atkinson Common Stock, $0.001 Par Value | 7.2 | 10,208,060.00 | 09/30/2025 Filed 2025-11-14 | SCHEDULE 13G/AAmendment 1 | Open filing 0001831942-25-000029 Dispute this row |
| Michael Kramarz Common Stock, $0.001 Par Value | 7.2 | 10,208,060.00 | 09/30/2025 Filed 2025-11-14 | SCHEDULE 13G/AAmendment 1 | Open filing 0001831942-25-000029 Dispute this row |
| Point72 Asset Management, L.P. Common Stock, par value $0.001 per share | 4.0 | 5,753,833.00 | 09/30/2025 Filed 2025-11-14 | SCHEDULE 13G/AAmendment 4 | Open filing 0000902664-25-005033 Dispute this row |
| Point72 Capital Advisors, Inc. Common Stock, par value $0.001 per share | 4.0 | 5,753,833.00 | 09/30/2025 Filed 2025-11-14 | SCHEDULE 13G/AAmendment 4 | Open filing 0000902664-25-005033 Dispute this row |
| Steven A. Cohen Common Stock, par value $0.001 per share | 4.0 | 5,753,833.00 | 09/30/2025 Filed 2025-11-14 | SCHEDULE 13G/AAmendment 4 | Open filing 0000902664-25-005033 Dispute this row |
| Paradigm BioCapital Advisors LP Common Stock, $0.001 par value per share | 2.3 | 3,156,398.00 | 09/30/2025 Filed 2025-11-14 | SCHEDULE 13G/AAmendment 3 | Open filing 0001104659-25-112634 Dispute this row |
| Paradigm BioCapital Advisors GP LLC Common Stock, $0.001 par value per share | 2.3 | 3,156,398.00 | 09/30/2025 Filed 2025-11-14 | SCHEDULE 13G/AAmendment 3 | Open filing 0001104659-25-112634 Dispute this row |
| Senai Asefaw, M.D. Common Stock, $0.001 par value per share | 2.3 | 3,156,398.00 | 09/30/2025 Filed 2025-11-14 | SCHEDULE 13G/AAmendment 3 | Open filing 0001104659-25-112634 Dispute this row |
| Paradigm BioCapital International Fund Ltd. Common Stock, $0.001 par value per share | 2.0 | 2,786,647.00 | 09/30/2025 Filed 2025-11-14 | SCHEDULE 13G/AAmendment 3 | Open filing 0001104659-25-112634 Dispute this row |
| Kynam Capital Management, LP Common Stock, par value $0.001 | 5.54 | 7,886,172 | 09/30/2025 Filed 2025-11-14 | SCHEDULE 13G/AAmendment 1 | Open filing 0001907884-25-000004 Dispute this row |
| Kynam Capital Management GP, LLC Common Stock, par value $0.001 | 5.54 | 7,886,172 | 09/30/2025 Filed 2025-11-14 | SCHEDULE 13G/AAmendment 1 | Open filing 0001907884-25-000004 Dispute this row |
| Yue Tang Common Stock, par value $0.001 | 5.54 | 7,886,172 | 09/30/2025 Filed 2025-11-14 | SCHEDULE 13G/AAmendment 1 | Open filing 0001907884-25-000004 Dispute this row |
| TCG Crossover GP I, LLC Common Stock, par value $0.001 per share | 4.8 | 6,798,162 | 09/30/2025 Filed 2025-11-14 | SCHEDULE 13G/AAmendment 4 | Open filing 0001193125-25-283076 Dispute this row |
| TCG Crossover Fund I, L.P. Common Stock, par value $0.001 per share | 4.8 | 6,798,162 | 09/30/2025 Filed 2025-11-14 | SCHEDULE 13G/AAmendment 4 | Open filing 0001193125-25-283076 Dispute this row |
| Chen Yu Common Stock, par value $0.001 per share | 4.8 | 6,798,162 | 09/30/2025 Filed 2025-11-14 | SCHEDULE 13G/AAmendment 4 | Open filing 0001193125-25-283076 Dispute this row |
| Fairmount Funds Management LLC Common Stock, $0.001 par value | 9.9 | 14,324,918.00 | 07/10/2025 Filed 2025-07-14 | SCHEDULE 13D/AAmendment 7 | Open filing 0001104659-25-067760 Dispute this row |
| Fairmount Healthcare Fund II GP LLC Common Stock, $0.001 par value | 9.9 | 14,324,918.00 | 07/10/2025 Filed 2025-07-14 | SCHEDULE 13D/AAmendment 7 | Open filing 0001104659-25-067760 Dispute this row |
| Commodore Capital LP Common Stock, $0.001 Par Value | 5.5 | 6,408,060.00 | 07/07/2025 Filed 2025-08-14 | SCHEDULE 13G | Open filing 0001831942-25-000016 Dispute this row |
| Commodore Capital Master LP Common Stock, $0.001 Par Value | 5.5 | 6,408,060.00 | 07/07/2025 Filed 2025-08-14 | SCHEDULE 13G | Open filing 0001831942-25-000016 Dispute this row |
| Robert Egen Atkinson Common Stock, $0.001 Par Value | 5.5 | 6,408,060.00 | 07/07/2025 Filed 2025-08-14 | SCHEDULE 13G | Open filing 0001831942-25-000016 Dispute this row |
| Michael Kramarz Common Stock, $0.001 Par Value | 5.5 | 6,408,060.00 | 07/07/2025 Filed 2025-08-14 | SCHEDULE 13G | Open filing 0001831942-25-000016 Dispute this row |
Percent is of the class the filing names, as the holder stated it. Members of a group each report the group’s shares, so rows are not added together.
What was read
2,708,462 filings read, dated 2004-06-14 to 2026-11-20: Forms 3, 3/A, 4, 4/A, 5, 5/A.
Years can be incomplete while the archive is still being read. A year with few filings here is not a statement that few were made.
| Filing year | Filings read |
|---|---|
| 2015 | 124,844 |
| 2016 | 222,642 |
| 2017 | 222,009 |
| 2018 | 223,345 |
| 2019 | 216,482 |
| 2020 | 226,343 |
| 2021 | 249,835 |
| 2022 | 231,682 |
| 2023 | 229,674 |
| 2024 | 234,045 |
| 2025 | 235,520 |
| 2026 | 263,828 |
Filings made before the SEC required XML are listed, not extracted.